Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis.
Idiopathic pulmonary fibrosis (IPF) has a high mortality rate, and current therapies are only marginally effective. A serum biomarker that predicts clinical outcome would be useful to stage disease, indicate prognosis and the need for aggressive therapy, and help stratify patients for clinical trials. The goals of this study were to determine whether serum levels of surfactant protein-A (SP-A) or surfactant protein-D (SP-D) would distinguish between IPF and other types of interstitial lung disease and whether serum SP-A or SP-D levels predict outcome in patients with IPF. The authors found that serum SP-A and SP-D levels were significantly elevated in patients with IPF and systemic sclerosis compared to sarcoidosis, beryllium disease and normal controls, and that SP-D correlated with radiographic abnormalities in patients with IPF. In addition, the authors found that both serum SP-A and SP-D levels were highly predictive of survival in patients with IPF. This is the largest North American data set of surfactant protein measurements in idiopathic pulmonary fibrosis and the first report using multivariate analysis comparing serum surfactant proteins-A and -D to other commonly measured predictors of survival in idiopathic pulmonary fibrosis. Based on these results, the authors propose that serum surfactant proteins may prove to be useful biomarkers in patients with idiopathic pulmonary fibrosis.
Greene
K E
KE
Dept of Medicine, National Jewish Medical and Research Centre, Denver, CO 80206, USA.
King
T E
TE
Kuroki
Y
Y
Bucher-Bartelson
B
B
Hunninghake
G W
GW
Newman
L S
LS
Nagae
H
H
Mason
R J
RJ
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000032:analysis; D015331:Cohort Studies; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006023:Glycoproteins / Q000032:analysis* / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011510:Proteolipids / Q000032:analysis*; D011658:Pulmonary Fibrosis / Q000097:blood / Q000175:diagnosis* / Q000401:mortality; D037663:Pulmonary Surfactant-Associated Protein D; D011663:Pulmonary Surfactants / Q000032:analysis* / Q000097:blood; D012016:Reference Values; D017565:Sarcoidosis, Pulmonary / Q000097:blood / Q000175:diagnosis* / Q000401:mortality; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D016019:Survival Analysis
D015415:Biomarkers; D006023:Glycoproteins; D011510:Proteolipids; D037663:Pulmonary Surfactant-Associated Protein D; D011663:Pulmonary Surfactants